CalciMedica (NASDAQ:CALC) Shares Down 2%

Shares of CalciMedica, Inc. (NASDAQ:CALC) traded down 2% during mid-day trading on Monday . The stock traded as low as $4.65 and last traded at $4.89. 30,659 shares traded hands during trading, a decline of 6% from the average session volume of 32,587 shares. The stock had previously closed at $4.99.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Singular Research raised CalciMedica to a “moderate buy” rating in a report on Friday, June 28th. Oppenheimer upped their target price on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of CalciMedica in a research note on Tuesday, August 13th.

CalciMedica Stock Down 7.7 %

The company’s fifty day moving average is $4.37 and its 200 day moving average is $4.65. The stock has a market cap of $46.66 million, a PE ratio of -2.01 and a beta of 1.27.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. Equities analysts expect that CalciMedica, Inc. will post -2.21 EPS for the current year.

Insider Buying and Selling at CalciMedica

In related news, Director Robert N. Wilson acquired 54,000 shares of CalciMedica stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the purchase, the director now directly owns 364,196 shares of the company’s stock, valued at approximately $1,354,809.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Robert N. Wilson acquired 54,000 shares of CalciMedica stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the purchase, the director now directly owns 364,196 shares of the company’s stock, valued at approximately $1,354,809.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert N. Wilson bought 8,443 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were acquired at an average cost of $3.23 per share, for a total transaction of $27,270.89. Following the completion of the acquisition, the director now directly owns 258,918 shares of the company’s stock, valued at approximately $836,305.14. The disclosure for this purchase can be found here. Insiders have purchased 78,443 shares of company stock worth $286,491 in the last ninety days. 53.30% of the stock is owned by insiders.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.